M&A Deal Summary |
|
|---|---|
| Date | 2017-08-31 |
| Target | Aptevo Therapeutics - Hyperimmune Commercial Products |
| Sector | Medical Products |
| Buyer(s) | Saol Therapeutics |
| Sellers(s) | Aptevo Therapeutics |
| Deal Type | Divestiture |
| Deal Value | 75M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Saol Therapeutics is a privately held specialty pharmaceutical company focused on providing therapies to patients with rare diseases. Saol Therapeutics has a strategic emphasis on the neurology therapeutic area. Saol Therapeutics was founded in 2015 and is based in Roswell, Georgia.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Washington) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2017) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-06 |
Saol Therapeutics - Baclofen Franchise
Roswell, Georgia, United States Saol Therapeutics' Baclofen Franchise is a pipeline product under development. Lioresal® is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. LYVISPAHTM is a baclofen oral granules (5, 10, and 20 mg) specialty product recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. Company leverage the innovative ADAPTIR platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 2 |
| State (Washington) | 1 of 1 |
| Country (United States) | 1 of 2 |
| Year (2017) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-02-28 |
IXINITY
Chicago, Illinois, United States IXINITY is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency. Hemophilia B is an inherited bleeding disorder that prevents clotting. |
Sell | $30M |
